Evidence
Clin Res Hepatol Gastroenterol. 2024 May 3:102366. doi: 10.1016/j.clinre.2024.102366. Online ahead of print.
NO ABSTRACT
PMID:38705235 | DOI:10.1016/j.clinre.2024.102366
Estimated reading time: 1 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Abnormal liver steatosis and fibrosis serum biomarker levels among psychiatric inpatients
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- Abnormal liver steatosis and fibrosis serum biomarker levels among psychiatric inpatients
- Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population
- The Pan Immune Inflammatory Value in Relation to Non-Alcoholic Fatty Liver Disease and Hepatic Fibrosis
- Efficacy and Safety of Aldafermin in Non-Alcoholic Steatohepatitis: A systematic review and meta-analysis of randomized controlled trials
- Resmetirom's Approval: Highlighting the Need for Comprehensive Approaches in NASH Therapeutics
- Strong association between sarcopenic obesity and non-alcoholic fatty liver disease: Anobservational study with ISarcoPRMalgorithm
- Probabilistic Scatter Plots for Visualizing Carbohydrate and Lipid Metabolism States in Non-Alcoholic Fatty Liver Disease
- Remnant cholesterol is associated with the progression and regression of metabolic dysfunction-associated steatotic liver disease in Chinese adults
- Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice
- Artificial Intelligence Chatbots in Healthcare: Navigating Accuracy, Privacy, and Global Applicability
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
- The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD)
- Comparative and Predictive Significance of Serum Leptin Levels in Non-alcoholic Fatty Liver Disease
- Resmetirom, the long-awaited first treatment for metabolic dysfunction-associated steatohepatitis and liver fibrosis?
- Research advances in serum chitinase-3-like protein 1 in liver fibrosis
- Research advances in serum chitinase-3-like protein 1 in liver fibrosis
- Discovery of genomic loci for liver health and steatosis reveals overlap with glutathione redox genetics
- Response to: The Synergism of Public Health Policies and Social Work May Reduce Mortality from Cancer, Liver Disease and Cardiovascular Disease
- Serum miR‑29 is increased in mice with early liver fibrosis
- Myeloid AMPK signaling restricts fibrosis but is not required for metformin improvements during CDAHFD-induced NASH in mice
- Progress of mesenchymal stem cells (MSCs) & MSC-Exosomes combined with drugs intervention in liver fibrosis
- Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis
- Angiocrine signaling in sinusoidal homeostasis and liver diseases
- Increased phosphatidylcholine and its hydroperoxides in serum low-density lipoproteins from patients with non-alcoholic steatohepatitis
- Increased phosphatidylcholine and its hydroperoxides in serum low-density lipoproteins from patients with non-alcoholic steatohepatitis
- Inflammation in alcohol-associated hepatitis: pathogenesis and therapeutic targets
- Letter to the Editor: Ketogenic diet time-dependently prevents nonalcoholic fatty liver disease through upregulating the expression of antioxidant protein metallothionein-2
- Letter to the Editor: Ketogenic diet time-dependently prevents nonalcoholic fatty liver disease through upregulating the expression of antioxidant protein metallothionein-2
- Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation
- Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation
- Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
- The role and mechanism of SUMO modification in liver disease
- Coexistence of metabolic-associated fatty liver disease and autoimmune or toxic liver disease
- Targeting antioxidant factor Nrf2 by raffinose ameliorates lipid dysmetabolism-induced pyroptosis, inflammation and fibrosis in NAFLD
- Letter to the editor: Relationship between educational attainment and non-alcoholic fatty liver disease: A two-sample Mendelian randomization study
- Multiscale 3D genome organization underlies duck fatty liver with no adipose inflammation or serious injury
- Androsin alleviates non-alcoholic fatty liver disease by activating autophagy and attenuating de novo lipogenesis
- Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives
- Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact
- Serum biomarkers for liver fibrosis assessment
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Tartaric acid ameliorates experimental non-alcoholic fatty liver disease by activating the AMP-activated protein kinase signaling pathway
- Tartaric acid ameliorates experimental non-alcoholic fatty liver disease by activating the AMP-activated protein kinase signaling pathway
- A PROTEIN COMPLEX OF LIVER ORIGIN ACTIVATES A PRO-INFLAMMATORY PROGRAM THAT DRIVES HEPATIC AND INTESTINAL INJURY IN ALCOHOL-ASSOCIATED LIVER DISEASE
- A PROTEIN COMPLEX OF LIVER ORIGIN ACTIVATES A PRO-INFLAMMATORY PROGRAM THAT DRIVES HEPATIC AND INTESTINAL INJURY IN ALCOHOL-ASSOCIATED LIVER DISEASE
- Unlock the potential: Auditory-evoked event-related potential (ERP) as a treatment-responsive biomarker for Rett syndrome
- A Validation Study of Non-invasive Scoring Systems for Assessing Severity of Hepatic Fibrosis in a Cohort of South Indian Patients With Non-alcoholic Fatty Liver Disease
- Antipsychotics use in autoimmune encephalitis and multiple sclerosis: Impact on hospitalization duration
- The challenge of artificial intelligence in medical writing and editing
- Baricitinib treatment in children with COPA syndrome
- Response to Bisol et al
- Artificial intelligence in medicine: Ethical, deontological aspects and the impact on the doctor-patient relationship
- Hepatokine ITIH3 protects against hepatic steatosis by downregulating mitochondrial bioenergetics and de novo lipogenesis
- The Role of the Pediatric Dermatologist in Childhood Bullying Prevention and Intervention: A Call to Action
- Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
- Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
- When Combating Dementia in Patients With Atrial Fibrillation Do Not Forget the Missing Bullet Holes
- When Combating Dementia in Patients With Atrial Fibrillation Do Not Forget the Missing Bullet Holes
- When Combating Dementia in Patients With Atrial Fibrillation Do Not Forget the Missing Bullet Holes
- Recurrence of Primary Disease After Adult Liver Transplant - Risk Factors, Early Diagnosis, Management, and Prevention
- Haloacetamides disinfection by-products, a potential risk factor for nonalcoholic fatty liver disease
- Letter Re: Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis
- The roles of extracellular vesicle-derived microRNAs in schizophrenia: A scoping review
- Autism spectrum disorder in children and young people with FND
Evidence Blueprint
Abnormal liver steatosis and fibrosis serum biomarker levels among psychiatric inpatients
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Abnormal liver steatosis and fibrosis serum biomarker levels among psychiatric inpatients
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- Abnormal liver steatosis and fibrosis serum biomarker levels among psychiatric inpatients
- Aspirin for Non Alcoholic Fatty Liver Disease: Promising but Inconclusive - A Letter to the editor
- Metabolism-related signalling pathways involved in the pathogenesis and development of metabolic dysfunction-associated steatotic liver disease
- Factors Associated with Discordance in the Assessment of Fibrosis Stage between Transient Elastography and Liver Biopsy in NAFLD Patients
- Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population
- The Pan Immune Inflammatory Value in Relation to Non-Alcoholic Fatty Liver Disease and Hepatic Fibrosis
- Efficacy and Safety of Aldafermin in Non-Alcoholic Steatohepatitis: A systematic review and meta-analysis of randomized controlled trials
- Resmetirom's Approval: Highlighting the Need for Comprehensive Approaches in NASH Therapeutics
- White Adipose Tissue in Metabolic Associated Fatty Liver Disease
- Increased Risk of Colorectal Adenomas with Metabolic-Associated Fatty Liver Disease Components
- Strong association between sarcopenic obesity and non-alcoholic fatty liver disease: Anobservational study with ISarcoPRMalgorithm
- Probabilistic Scatter Plots for Visualizing Carbohydrate and Lipid Metabolism States in Non-Alcoholic Fatty Liver Disease
- Independent and joint association of physical activity and adequate weekday sleep duration with metabolic dysfunction-associated steatotic liver disease
- Granulocyte Colony Stimulating Factor in decompensated cirrhosis, acute alcoholic hepatitis, and acute-on-chronic liver failure: a comprehensive meta-analysis of randomized controlled trials
- Remnant cholesterol is associated with the progression and regression of metabolic dysfunction-associated steatotic liver disease in Chinese adults
- Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice
- Artificial Intelligence Chatbots in Healthcare: Navigating Accuracy, Privacy, and Global Applicability
- Corrigendum to "SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease" [J Hepatol 80 (2024) 10-19]
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
- Compromised very-low density lipoprotein induced polyunsaturated triglyceride accumulation in N-nitrosodiethylamine-induced hepatic steatosis
- The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD)
- Comparative and Predictive Significance of Serum Leptin Levels in Non-alcoholic Fatty Liver Disease
- Resmetirom, the long-awaited first treatment for metabolic dysfunction-associated steatohepatitis and liver fibrosis?
- ALT Poorly Predicts Nonalcoholic Fatty Liver Disease (NAFLD) and Liver Fibrosis as Determined by Vibration-Controlled Transient Elastography in Adult National Health and Nutrition Examination Survey 2017-2018: ALT Poorly Predicts NAFLD and…
- Evaluation of Antisense Oligonucleotides Therapy Targeting Hsd17b13 in a Fibrosis Mice Model
- Recruitment or activation of mast cells in the liver aggravates the accumulation of fibrosis in carbon tetrachloride-induced liver injury
- Research advances in serum chitinase-3-like protein 1 in liver fibrosis
- Research advances in serum chitinase-3-like protein 1 in liver fibrosis
- Performance of FibroScan in grading steatosis and fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis
- ALCOHOLIC FOAMY DEGENERATION, AN ENTITY RESEMBLING ALCOHOL-ASSOCIATED HEPATITIS: DIAGNOSIS, PROGNOSIS AND MOLECULAR PROFILING
- Discovery of genomic loci for liver health and steatosis reveals overlap with glutathione redox genetics
- Response to: The Synergism of Public Health Policies and Social Work May Reduce Mortality from Cancer, Liver Disease and Cardiovascular Disease
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Serum miR‑29 is increased in mice with early liver fibrosis
- Chronic unpredictable mild stress increases serum aldosterone without affecting corticosterone levels and induces hepatic steatosis and renal injury in young adult male rats
- Myeloid AMPK signaling restricts fibrosis but is not required for metformin improvements during CDAHFD-induced NASH in mice
- Role of Angiotensin II in Non-Alcoholic Steatosis Development
- A Novel cause of Massive Hepatosplenomegaly with Fibrosis in two children: Transient Infantile Hypertriglyceridemia
- Targeted platelet with hydrogen peroxide responsive behavior for non-alcoholic steatohepatitis detection
- Progress of mesenchymal stem cells (MSCs) & MSC-Exosomes combined with drugs intervention in liver fibrosis
- Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis
- The protective effect of Enteromorpha prolifera polysaccharide on alcoholic liver injury in C57BL/6 mice
- Various types of fasting diet and possible benefits in nonalcoholic fatty liver: Mechanism of actions and literature update
- Angiocrine signaling in sinusoidal homeostasis and liver diseases
- Increased phosphatidylcholine and its hydroperoxides in serum low-density lipoproteins from patients with non-alcoholic steatohepatitis
- Increased phosphatidylcholine and its hydroperoxides in serum low-density lipoproteins from patients with non-alcoholic steatohepatitis
- Inflammation in alcohol-associated hepatitis: pathogenesis and therapeutic targets
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Fibroblast growth factor 19 alters bile acids to induce dysbiosis in mice with alcohol-induced liver disease
- Fibroblast growth factor 19 alters bile acids to induce dysbiosis in mice with alcohol-induced liver disease
- Increased frequency of hepatic steatosis and fibrosis in patients with gout detected by transient elastography
- Diagnostic Performance of Quantitative Ultrasound Parameters in Non-alcoholic Fatty Liver Disease
- Specific targeting of the NRF2/β-TrCP axis promotes beneficial effects in NASH
- Letter to the Editor: Ketogenic diet time-dependently prevents nonalcoholic fatty liver disease through upregulating the expression of antioxidant protein metallothionein-2
- Letter to the Editor: Ketogenic diet time-dependently prevents nonalcoholic fatty liver disease through upregulating the expression of antioxidant protein metallothionein-2
- Imbalance of mitochondrial fusion in peripheral blood mononuclear cells is associated with liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis
- Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation
- Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation
- Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
- Liver fibrosis in pars cohort study: A large-scale study on the prevalence and correlated factors
- The role and mechanism of SUMO modification in liver disease
- Brain-derived neurotrophic factor levels across psychiatric disorders: A systemic review and network meta-analysis
- Performance of non-invasive tests for liver fibrosis and resolution after bariatric surgery
- Vitamin D(3) exacerbates steatosis while calcipotriol inhibits inflammation in non-alcoholic fatty liver disease in Sod1 knockout mice: a comparative study of two forms of vitamin D